Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 20;11(5):1004.
doi: 10.3390/antiox11051004.

Redox-Active Molecules as Therapeutic Agents

Ana Sofia Fernandes  1
Affiliations
Editorial

Redox-Active Molecules as Therapeutic Agents

Ana Sofia Fernandes. Antioxidants (Basel). .

Abstract

Oxidative stress and altered redox signaling have been described in a plethora of pathological conditions, such as inflammation, cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders, among others [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Egea J., Fabregat I., Frapart Y.M., Ghezzi P., Görlach A., Kietzmann T., Kubaichuk K., Knaus U.G., Lopez M.G., Olaso-Gonzalez G., et al. European Contribution to the Study of ROS: A Summary of the Findings and Prospects for the Future from the COST Action BM1203 (EU-ROS) Redox Biol. 2017;13:94–162. doi: 10.1016/j.redox.2017.05.007. - DOI - PMC - PubMed
    1. Flórido A., Saraiva N., Cerqueira S., Almeida N., Parsons M., Batinic-Haberle I., Miranda J.P., Costa J.G., Carrara G., Castro M., et al. The Manganese(III) Porphyrin MnTnHex-2-PyP5+ Modulates Intracellular ROS and Breast Cancer Cell Migration: Impact on Doxorubicin-Treated Cells. Redox Biol. 2019;20:367–378. doi: 10.1016/j.redox.2018.10.016. - DOI - PMC - PubMed
    1. Mirzaei S., Zarrabi A., Hashemi F., Zabolian A., Saleki H., Azami N., Hamzehlou S., Farahani M.V., Hushmandi K., Ashrafizadeh M., et al. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants. 2021;10:349. doi: 10.3390/antiox10030349. - DOI - PMC - PubMed
    1. Manguinhas R., Fernandes A.S., Costa J.G., Saraiva N., Camões S.P., Gil N., Rosell R., Castro M., Miranda J.P., Oliveira N.G. Impact of the APE1 Redox Function Inhibitor E3330 in Non-Small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and Invasion. Antioxidants. 2020;9:550. doi: 10.3390/antiox9060550. - DOI - PMC - PubMed
    1. Ferreira S., Saraiva N., Rijo P., Fernandes A.S. LOXL2 Inhibitors and Breast Cancer Progression. Antioxidants. 2021;10:312. doi: 10.3390/antiox10020312. - DOI - PMC - PubMed

Publication types

LinkOut - more resources